Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade
Ontario Institute for Cancer Research · Howard Hughes Medical Institute · +2 more institutions
Abstract
Dopamine (DA) is a neurotransmitter involved in the control of locomotion, emotion, cognition, and reward. Administration of lithium salts is known to inhibit DA-associated behaviors in experimental animal models through unknown mechanisms. Here, we used a pharmacogenetic approach to show that DA can exert its behavioral effects by acting on a lithium-sensitive signaling cascade involving Akt/PKB and glycogen synthase kinase 3 (GSK-3). In the mouse striatum, increased DA neurotransmission arising either from administration of amphetamine or from the lack of the DA transporter results in inactivation of Akt and concomitant activation of GSK-3alpha and GSK-3beta. These biochemical changes are not affected by…
Citation impact
- FWCI
- 11.78
- Percentile
- 100%
- References
- 47
Authors
7- JBJean‐Martin Beaulieu
Ontario Institute for Cancer Research, Howard Hughes Medical Institute, Duke Medical Center
- TDTatyana D. Sotnikova
Ontario Institute for Cancer Research, Howard Hughes Medical Institute, Duke Medical Center, Duke University Hospital
- WYWei‐Dong Yao
Ontario Institute for Cancer Research, Howard Hughes Medical Institute, Duke Medical Center, Duke University Hospital
- LKLisa Kockeritz
Ontario Institute for Cancer Research, Howard Hughes Medical Institute, Duke Medical Center
- JRJames R. Woodgett
Ontario Institute for Cancer Research, Howard Hughes Medical Institute, Duke Medical Center
Topics & keywords
- GSK-3
- Protein kinase B
- Dopamine
- Glycogen synthase
- Lithium (medication)
- Dopamine receptor D2
- Pharmacology
- Amphetamine
- Good health and well-being